

Liquid biopsies in the clinic

Klaus Pantel and Caroline Dive



The concept of 'liquid biopsy' refers to the detection of molecules that originate from tumours, by analysis of intact circulating tumour cells (CTCs), circulating tumour DNA (ctDNA), microRNAs (miRNAs) and exosomes. A number of cellular processes, such as epithelial-to-mesenchymal transition, collective migration, cell co-operation or vasculogenic mimicry,

are associated with intravasation and extravasation of tumour components¹. The mechanisms whereby ctDNA enters the bloodstream remain understudied; however, the prevailing view is that ctDNA is released from dying cells². Exosomes are small microvesicles that are released into the blood by normal and malignant cells, and contain proteins, nucleic acids and lipids³.

CTCs can disseminate as single cells or as clusters, and are thought to be harbingers of metastases². DNA released from tumour cells into the circulation can also be detected in the blood of patients with cancer and reveal information on the molecular evolution of cancer². Exosomes that are present in liquid biopsies (such as blood plasma) are promising novel candidate blood-based biomarkers of tumour progression and resistance to therapy³. miRNAs have good stability and are being explored as biomarkers that enable screening and/or early detection⁴.

Studying liquid biopsies at different times of tumour progression offers a wealth of information on:

- disease stage and tumour heterogeneity
- selection of targeted therapies
- response to treatment and
- the emergence of therapy resistance and its underlying mechanisms

Chemotherapy
Radiotherapy
SurgeryChemotherapy
Targeted therapyChemotherapy
Targeted therapyTumour
evolution

Screening and early detection of cancer

Circulating biomarkers for cancer screening and early detection have often emerged from comparative longitudinal studies of healthy individuals, patients with benign disease and patients with cancer. The process of biomarker validation is facilitated by focussing on individuals at a high risk of developing cancer.

Owing to low CTC numbers and ctDNA concentrations in the bloodstream of individuals at risk, liquid biopsy assay sensitivity is a technical challenge for detection of early malignant lesions. The clinical challenge is to minimize false-positive test results that can be associated with anxiety⁵, and provoke additional unnecessary diagnostic procedures. Developing the 'right' panel of cancer-specific genomic aberrations to distinguish individuals with cancer from healthy individuals or from those with benign disease is of utmost importance, but requires substantial resources.

Estimation of relapse risk

Tumour staging (estimation of an individual's risk of progression at the time of diagnosis) guides the decision on the most appropriate therapy aimed to eradicate all tumour cells and prevent local and/or disseminated disease relapse. Numerous studies have shown the prognostic value of CTCs expressing epithelial marker proteins (such as EpCAM and/or cytokeratin) in patients with solid tumours without clinical or radiological signs of overt distant metastases at primary diagnosis, in particular, in patients with breast cancer⁶.

Liquid biopsies enable post-surgical surveillance of minimal residual disease (MRD) aiming to detect relapse before imaging or clinical symptoms report potential overt metastatic disease. However, CTC numbers and ctDNA concentrations are often low, requiring ultrasensitive technologies.

Analysis of liquid biopsy samples from the proximal draining veins of cancerous organs at the time of surgical resection with curative intent might enable identification of those patients at risk of recurrence. If candidate biomarkers have been first defined in the resected tumour, longitudinal profiling of 'early' CTCs and/or ctDNA might inform on treatment of recurrent disease. Studies on the kinetics of MRD can also provide valuable insights into the biology of cancer dormancy.

Identification of therapeutic targets for precision medicine

Liquid biopsies are beginning to fulfil their potential as prognostic, predictive, and pharmacodynamic biomarkers, and are being used for longitudinal monitoring of tumour evolution and emergent treatment resistance. Examples of biomarkers detected in liquid biopsies to guide precision medicine approaches include:

Gene expression

- Breast cancer: oestrogen receptor (*ESR1*), *HER2* oncogene and immune-checkpoint regulators, such as *PDL1* in CTCs⁷
- Prostate cancer: expression, activation and signalling mediated by the androgen receptor (*AR*) as a target of antiandrogen therapy (for example, *AR* splice variant 7) in CTCs⁸

Genomic aberrations

Mutations in genes encoding therapeutic targets and downstream effectors can affect drug efficacy; for example, *EGFR* mutations in ctDNA from lung cancer, *KRAS* mutations in CTCs from colorectal cancer, *ESR* and *PIK3CA* mutations in ctDNA and CTCs from breast cancer, *AR* amplifications and mutations in CTCs and ctDNA from prostate cancer, and *BRAF* mutations in CTCs and ctDNA from melanoma.

Real-time monitoring of response to therapy and anticipation of emergent therapy resistance

Sequential CTC and ctDNA analyses have the potential to inform on the optimal time to switch therapies:

- Breast cancer: CTC counts to predict chemotherapy effectiveness; ctDNA analysis to map subclonal evolution⁹
- Prostate cancer: CTC counts as an individual-level surrogate for patient survival in metastatic castration-resistant prostate cancer in the context of antiandrogen therapy; detection of *AR* gene aberrations in ctDNA to enable prediction of the outcomes of androgen-deprivation therapy
- Melanoma: dynamic changes of *BRAF* mutations in ctDNA to monitor therapy response¹⁰
- Colorectal cancer: ctDNA analysis to track clonal evolution and acquired resistance to *EGFR*-targeted therapies (often associated with emergence of *KRAS* mutations¹¹)

Liquid biopsy assays now need to be standardized and cross-validated within international consortia (for example, the European IMI consortium (www.cancer-id.eu) and the utility of liquid-biopsy-based clinical decision-making now needs to be demonstrated in randomized clinical interventional studies incorporating established end points (such as time-to-progression or overall survival).

Utility of CTC cultures and CTC-derived patient explants

Patient-derived CTCs can be cultured *in vitro* and show substantial promise for real-time assessment of treatment efficacy as part of a personalized medicine approach^{12,13}.

CTC-derived explant models (CDX) are generated directly from CTC-enriched blood samples from patients and have been developed for breast cancer, small-cell lung cancer and melanoma. These models do not constitute 'avatars' because the time to model development is lengthy, but they do provide a faithful platform for the identification of new therapeutic targets and therapy testing¹⁴.

References

1. Nieto, M. A. *et al.* EMT: 2016. *Cell* **166**, 21–45 (2016).
2. Alix-Panabières, C. & Pantel, K. Clinical applications of circulating tumour cells and circulating tumour DNA as liquid biopsy. *Cancer Discov.* **6**, 479–491 (2016).
3. An, T. *et al.* Exosomes serve as tumour markers for personalized diagnostics owing to their important role in cancer metastasis. *J. Extracell. Vesicles* **4**, 27522 (2015).
4. Sozzi, G. *et al.* Clinical utility of a plasma-based miRNA signature classifier within computed tomography lung cancer screening: a correlative MILD trial study. *J. Clin. Oncol.* **32**, 768–773 (2015).
5. Newman, A. M. *et al.* Integrated digital error suppression for improved detection of circulating tumour DNA. *Nat. Biotechnol.* **34**, 547–555 (2016).
6. Janni, W. J. *et al.* Pooled analysis of the prognostic relevance of circulating tumour cells in primary breast cancer. *Clin. Cancer Res.* **22**, 2583–2593 (2016).
7. Mazel, M. *et al.* Frequent expression of PD-L1 on circulating breast cancer cells. *Mol. Oncol.* **9**, 1773–1782 (2015).
8. Antonarakis, E. S. *et al.* AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. *N. Engl. J. Med.* **371**, 1028–1038 (2014).
9. Dawson, S. J. *et al.* Analysis of circulating tumour DNA to monitor metastatic breast cancer. *N. Engl. J. Med.* **368**, 1199–1209 (2013).

10. Girotti, M. R. *et al.* Application of sequencing, liquid biopsies, and patient-derived xenografts for personalized medicine in melanoma. *Cancer Discov.* **6**, 286–299 (2016).
11. Siravegna, G. & Bardelli, A. Blood circulating tumour DNA for non-invasive genotyping of colon cancer patients. *Mol. Oncol.* **10**, 475–480 (2016).
12. Yu, M. *et al.* Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. *Science* **339**, 580–584 (2013).
13. Cayrefourcq, L. *et al.* Establishment and characterization of a cell line from human circulating colon cancer cells. *Cancer Res.* **75**, 892–901 (2015).
14. Hodgkinson, C. L. *et al.* Tumorigenicity and genetic profiling of circulating tumour cells in small-cell lung cancer. *Nat. Med.* **20**, 897–903 (2014).

Klaus Pantel is the Chairman of the Department of Tumor Biology, Center of Experimental Medicine, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246 Hamburg, Germany.

Caroline Dive is at the Pharmacology Group of the Cancer Research UK Manchester Institute, University of Manchester, Wilmslow Road, Manchester, M20 4BX, UK.

Correspondence to K.P. and C.D. pantel@uke.de caroline.dive@cruk.manchester.ac.uk

Author disclosures

Both authors receive support from CANCER-ID, an Innovative Medicines Initiative Joint Undertaking under grant agreement n° 115749, resources of which are composed of financial contribution from the European Union's Seventh Framework Program (FP7/2007–2013) and the European Federation of Pharmaceutical Industries and Associations in kind contribution. The work of the authors has been further supported by the European Research Council Advanced Investigator grant 269081 DISSECT (to K.P.), and by grants from Cancer Research UK (C5759/A20971) and Menarini Silicon Biosystems (to C.D.).

The poster content is peer reviewed, editorially independent and the sole responsibility of Macmillan Publishers Limited.

Edited by Diana Romero; designed by Simon Bradbrook. © 2016 Macmillan Publishers Limited. All rights reserved. <http://www.nature.com/nrclinonc/posters/liquidbiopsies/index.html>

Poster produced with financial support from:



Sponsor's message — Menarini Silicon Biosystems

Menarini Silicon Biosystems is the biotech company that developed DEPArray™ NxT an innovative benchtop instrument that provides precision liquid biopsy analysis at the single-cell level. DEPArray™ NxT can isolate single circulating tumour cells (CTCs) from enriched blood with 100% precision for an accurate molecular characterization. In addition, pure tumour cells from FFPE and FNA biopsies can also be isolated. Cells sorted with DEPArray™ NxT are suitable for very precise and reproducible next-generation sequencing (NGS) analysis, copy-number aberration analysis by low-pass genome sequencing, whole-exome sequencing or analysis of somatic mutations by targeted sequencing. Such unprecedented results enable monitoring of disease progression, unveil the drivers of cancer evolution and open the door to actionable insights toward understanding the genetic profile of individual tumours. Menarini Silicon Biosystems also developed the Ampli1™ product line, a variety of kits for whole-genome and whole-transcriptome amplification and downstream analysis at the single-cell level. DEPArray™ NxT represents a robust laboratory workflow enhancement and a fundamental step in the developing of personalized medicine. To learn more about our solutions for liquid biopsy visit us at www.siliconbiosystems.com